Sector: Leem mobilizes once morest drug shortages
The drug companiest (Leem) took part in a meeting with Ministers of Health and Industry to develop a new roadmap to tackle drug shortages. Welcoming this initiative led by the government, the union intends in particular to define a list of critical drugs by the end of May, map industrial risks and improve information tools for patients and health professionals.
“It was essential to take strong measures. I salute the efforts to protect the price and revalue essential “old” medicines. But this upgrading must not be done at the expense of innovative therapies in France. More than ever, it is urgent to review the budget envelope of the drug “, commented Thierry Hulot, the president of Leem. The union should soon announce its proposals, as he had the opportunity to do in 2019, during the development of the previous government roadmap and says he is “particularly attentive to the financing of government announcements. »
VOS INDICES
source
Genetic diseases: BNP Paribas and Imagine sign a sponsorship partnership
BNP Paribas Cardif France and theInstitut Imagine will join forces to accelerate medical research in the field of genetic diseases. In concrete terms, BNP Paribas Cardif, a loan insurance specialist belonging to BNP Paribas, will take on the role of “benefactor” for the three-year Imagine program, called Springboard. This initiative aims in particular to encourage the creation of start-ups dedicated to genetic diseases, to transform research results into innovations or diagnostic and therapeutic solutions, but also to raise awareness of this type of pathology.
“Since our desire is to bring treatments to patients as quickly as possible, we have created a unique acceleration tool, called Springboard, whose ambition is to finance and grow projects in order to bring them to the creation of start-ups », underlined Stanislas Lyonnet, the director of the Imagine Institute. Rare diseases, 80% of which have a genetic origin, affect nearly three million people in France.
Healthtech : France Biotech s’associe au CCE
France Biotech has formed a partnership with the advisers of the Foreign trade of France (CCE) to develop the competitiveness and attractiveness of French healthtech companies. The signing of this agreement aims in particular to support companies in the sector in their international development by providing them with the expertise and skills of CCEs. Scheduled to last two years and steered by a joint CCE/France Biotech committee, this initiative is part of the Team France Export system.
“As part of France 2030, our companies must be strong on their territory, but also for export. Experience and feedback from the field will be valuable to our entrepreneurs in a number of target countries in terms of potential market or development. It is an opportunity to be able to call on these French experts who are in these territories”said Franck Mouthon, President of France Biotech.
Selected for you
